The Immune Pathogenesis of Scleroderma: Context Is Everything

SCLERODERMA (J VARGA, SECTION EDITOR)
Part of the following topical collections:
  1. Topical Collection on Scleroderma

Abstract

The fundamental mechanisms that drive the pathogenesis of systemic sclerosis (SSc) remain elusive, despite over 50 years of investigation. Here, we review recent progress in the understanding of the immunopathogenesis of SSc. In particular, we consider interleukin-13 (IL13), and its upstream and downstream pathways, as an example of an immune system-derived mediator involved in fibrotic and vascular pathology. Emerging results linking pattern-recognition receptors and interferon pathways to SSc are also stressed. We discuss genetic data linking the immune system to SSc risk and efforts to apply animal models to subsets of patients recently resolved by gene expression profiling. These developments will help build a context for better understanding of previous observations and design of the next generation of studies that may eventually lead to effective treatment.

Keywords

Scleroderma Systemic sclerosis Animal models Interleukin-13 Interleukin-33 Toll-like receptor 3 Interferon Immune Pathogenesis 

Notes

Acknowledgments

Dr Aliprantis is supported by grants from the Burroughs Wellcome Fund and the National Institutes of Health (K08 AR 054859 and R01 AR060363). Dr Aliprantis’ work relevant to SSc was previously supported by the Scleroderma Research Foundation and Sanofi pharmaceuticals. The authors thank Drs Julia Charles, Susan Ritter, and Joerg Ermann for their thoughtful review and discussion of this manuscript.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Strehlow D, Korn JH. Biology of the scleroderma fibroblast. Curr Opin Rheumatol. 1998;10(6):572–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol. 1999;120(3):169–76.PubMedCrossRefGoogle Scholar
  3. 3.
    Stone OJ. Autoimmunity as a secondary phenomenon in scleroderma (and so-called human adjuvant disease). Med Hypotheses. 1991;34(2):127–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2(6):863–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Zhou X, Lee JE, Arnett FC, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum. 2009;60(12):3807–14.PubMedCrossRefGoogle Scholar
  6. 6.
    •• Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010;42(5):426–9. This paper reports the findings of a large GWAS study of SSc, identifying the CD247 locus as involved and confirming previous observations regarding the MHC locus, IRF5, and STAT4.PubMedCrossRefGoogle Scholar
  7. 7.
    • Allanore Y, Saad M, Dieude P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 2011;7(7):e1002091. This GWAS study of SSc confirms the linkage with MHC and identifies the TNIP1, RHOB, and PSORS1C1 loci as involved.PubMedCrossRefGoogle Scholar
  8. 8.
    Sharif R, Mayes MD, Tan FK, et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis. 2012;71(7):1197–202.PubMedCrossRefGoogle Scholar
  9. 9.
    Bossini-Castillo L, Martin JE, Broen J, et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet. 2012;21(4):926–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Bossini-Castillo L, Simeon CP, Beretta L, et al. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther. 2012;14(2):R85.PubMedCrossRefGoogle Scholar
  11. 11.
    Bossini-Castillo L, Broen JC, Simeon CP, et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis. 2011;70(4):638–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Broen JC, Coenen MJ, Radstake TR. Genetics of systemic sclerosis: an update. Curr Rheumatol Rep. 2012;14(1):11–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Romano E, Manetti M, Guiducci S, et al. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S75–86.PubMedGoogle Scholar
  14. 14.
    Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 2010;62(10):2831–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Sargent JL, Whitfield ML. Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol. 2011;7(4):463–73.PubMedCrossRefGoogle Scholar
  16. 16.
    LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–5.PubMedGoogle Scholar
  17. 17.
    Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3(7):e2696.PubMedCrossRefGoogle Scholar
  18. 18.
    •• Pendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol. 2012;132(5):1363–73. This work extends the results of Milano et al., furnishing evidence that the SSc subsets identified are stable and may not simply reflect different stages during the development of SSc.PubMedCrossRefGoogle Scholar
  19. 19.
    Yamamoto T. Animal model of systemic sclerosis. J Dermatol. 2010;37(1):26–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Artlett CM. Animal models of scleroderma: fresh insights. Curr Opin Rheumatol. 2010;22(6):677–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol. 1983;77(1):1–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Fleming JN, Shulman HM, Nash RA, et al. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One. 2009;4(7):e6203.PubMedCrossRefGoogle Scholar
  23. 23.
    Ruzek MC, Jha S, Ledbetter S, et al. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 2004;50(4):1319–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaplan DH, Anderson BE, McNiff JM, et al. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173(9):5467–75.PubMedGoogle Scholar
  25. 25.
    •• Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol. 2012;180(3):1080–94. Here we describe the contribution of IL-13 to the SclGVHD model, including the cellular sources and effects of IL-13. Also, molecular profiling of the SclGVHD model is used to map it to the inflammatory subset of SSc patients.PubMedCrossRefGoogle Scholar
  26. 26.
    McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-b treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693–9.PubMedGoogle Scholar
  27. 27.
    Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40(3):241–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5(4):200–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Abraham D. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford). 2008;47 Suppl 5:v8–9.CrossRefGoogle Scholar
  30. 30.
    Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47 Suppl 5:v2–4.CrossRefGoogle Scholar
  31. 31.
    Silver RM. Endothelin and scleroderma lung disease. Rheumatology (Oxford). 2008;47 Suppl 5:v25–6.CrossRefGoogle Scholar
  32. 32.
    Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362(6417):248–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002;109(10):1351–9.PubMedGoogle Scholar
  34. 34.
    Bellinghausen I, Brand P, Bottcher I, et al. Production of interleukin-13 by human dendritic cells after stimulation with protein allergens is a key factor for induction of T helper 2 cytokines and is associated with activation of signal transducer and activator of transcription-6. Immunology. 2003;108(2):167–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Kim EY, Battaile JT, Patel AC, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 2008;14(6):633–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Barlow JL, McKenzie AN. Nuocytes: expanding the innate cell repertoire in type-2 immunity. J Leukoc Biol. 2011;90(5):867–74.PubMedCrossRefGoogle Scholar
  37. 37.
    • Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70. With Refs. [38] and [39], this paper identifies nuocytes as a novel IL-13-producing, IL-25 and IL33-responsive, innate immune cell.PubMedCrossRefGoogle Scholar
  38. 38.
    • Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463(7280):540–4. With Refs. [37] and [39], this paper identifies a novel IL13-producing population that responds to IL-25.PubMedCrossRefGoogle Scholar
  39. 39.
    • Price AE, Liang HE, Sullivan BM, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA. 2010;107(25):11489–94. With Refs. [37] and [38], this paper identifies systemically dispersed lineage negative cell that secretes IL-13 in response to IL-25 and IL33.PubMedCrossRefGoogle Scholar
  40. 40.
    Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701–38.PubMedCrossRefGoogle Scholar
  41. 41.
    Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300(5625):1527–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Tabata Y, Khurana Hershey GK. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep. 2007;7(5):338–45.PubMedCrossRefGoogle Scholar
  43. 43.
    Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol. 1998;161(5):2317–24.PubMedGoogle Scholar
  44. 44.
    Murata T, Husain SR, Mohri H, Puri RK. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol. 1998;10(8):1103–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Daines MO, Tabata Y, Walker BA, et al. Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling. J Immunol. 2006;176(12):7495–501.PubMedGoogle Scholar
  46. 46.
    Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197(6):703–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med. 2003;197(6):687–701.PubMedCrossRefGoogle Scholar
  48. 48.
    Leigh R, Ellis R, Wattie J, et al. Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am J Respir Crit Care Med. 2004;170(8):851–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Fichtner-Feigl S, Young CA, Kitani A et al.: IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008, 135(6):2003–2013, 2013 e2001-2007.Google Scholar
  50. 50.
    Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99–106.PubMedCrossRefGoogle Scholar
  51. 51.
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24(2):328–32.PubMedGoogle Scholar
  52. 52.
    Fuschiotti P, Medsger Jr TA, Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 2009;60(4):1119–28.PubMedCrossRefGoogle Scholar
  53. 53.
    Medsger Jr TA, Ivanco DE, Kardava L, et al. GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum. 2011;63(6):1738–47.PubMedCrossRefGoogle Scholar
  54. 54.
    Sweiss NJ, Hushaw L, Thenappan T, et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep. 2010;12(1):8–18.PubMedCrossRefGoogle Scholar
  55. 55.
    Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011;63(6):1718–28.PubMedCrossRefGoogle Scholar
  56. 56.
    Riccieri V, Rinaldi T, Spadaro A, et al. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol. 2003;22(2):102–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6(10):578–87.PubMedCrossRefGoogle Scholar
  58. 58.
    Granel B, Allanore Y, Chevillard C, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol. 2006;33(10):2015–9.PubMedGoogle Scholar
  59. 59.
    Granel B, Chevillard C, Allanore Y, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics. 2006;58(8):693–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Broen JC, Dieude P, Vonk MC, et al. Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. J Rheumatol. 2012;39(1):112–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779–88.PubMedCrossRefGoogle Scholar
  62. 62.
    Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129(3):742–51.PubMedCrossRefGoogle Scholar
  63. 63.
    Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol. 2004;135(4):348–56.PubMedCrossRefGoogle Scholar
  64. 64.
    Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA. 2007;104(8):2827–30.PubMedCrossRefGoogle Scholar
  65. 65.
    Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27(4):419–27.PubMedGoogle Scholar
  66. 66.
    Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.PubMedCrossRefGoogle Scholar
  67. 67.
    Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777–90.PubMedCrossRefGoogle Scholar
  68. 68.
    Zhu Z, Ma B, Zheng T, et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2002;168(6):2953–62.PubMedGoogle Scholar
  69. 69.
    Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol. 2011;7(6):321–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90.PubMedCrossRefGoogle Scholar
  71. 71.
    Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179(4):2551–5.PubMedGoogle Scholar
  72. 72.
    Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA. 2012;109(5):1673–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188(7):3488–95.PubMedCrossRefGoogle Scholar
  75. 75.
    Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med. 2010;269(1):29–35.CrossRefGoogle Scholar
  76. 76.
    Manetti M, Ibba-Manneschi L, Liakouli V, et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis. 2010;69(3):598–605.PubMedCrossRefGoogle Scholar
  77. 77.
    Yanaba K, Yoshizaki A, Asano Y, et al. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol. 2011;30(6):825–30.PubMedCrossRefGoogle Scholar
  78. 78.
    Manetti M, Guiducci S, Ceccarelli C, et al. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis. 2011;70(10):1876–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22.CrossRefGoogle Scholar
  80. 80.
    Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82(6):1481–90.PubMedCrossRefGoogle Scholar
  81. 81.
    Smithgall MD, Comeau MR, Yoon BR, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20(8):1019–30.PubMedCrossRefGoogle Scholar
  82. 82.
    Rankin AL, Mumm JB, Murphy E, et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol. 2009;184(3):1526–35.PubMedCrossRefGoogle Scholar
  83. 83.
    Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res. 2006;297(8):333–44.PubMedCrossRefGoogle Scholar
  84. 84.
    Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford). 2006;45(6):694–702.CrossRefGoogle Scholar
  85. 85.
    York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 2007;56(3):1010–20.PubMedCrossRefGoogle Scholar
  86. 86.
    Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–8.PubMedCrossRefGoogle Scholar
  87. 87.
    •• Farina GA, York MR, Di Marzio M, et al. Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol. 2010;130(11):2583–93. This paper identifies expression of type I interferon and TGFβ target genes in the skin of SSc patients and demonstrates that chronic subcutaneous infusion of type I interferon eliciting poly I:C stimulates inflammation and fibrosis.PubMedCrossRefGoogle Scholar
  88. 88.
    Farina G, York M, Collins C, Lafyatis R. dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann Rheum Dis. 2011;70(3):544–50.PubMedCrossRefGoogle Scholar
  89. 89.
    Cavassani KA, Ishii M, Wen H, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008;205(11):2609–21.PubMedCrossRefGoogle Scholar
  90. 90.
    White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am. 1996;22(4):695–708.PubMedCrossRefGoogle Scholar
  91. 91.
    Roumm AD, Whiteside TL, Medsger Jr TA, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984;27(6):645–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Matthew B. Greenblatt
    • 1
    • 3
  • Antonios O. Aliprantis
    • 2
    • 4
  1. 1.Department of PathologyBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Department of Medicine, Division of Rheumatology, Allergy and ImmunologyBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Department of PathologyBrigham and Women’s HospitalBostonUSA
  4. 4.Department of Medicine, Division of Rheumatology, Allergy and ImmunologyBostonUSA

Personalised recommendations